Enterprise Value

19.82M

Cash

37.02M

Avg Qtr Burn

-6.953M

Short % of Float

4.81%

Insider Ownership

4.09%

Institutional Own.

45.55%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Mupadolimab (CPI-006) (Anti-CD73) Details
Renal cell carcinoma, Lung cancer, Cancer, Non-small cell lung carcinoma

Phase 2

Update

Phase 2

Initiation

Ciforadenant (A2AR inhibitor) +/- ipilimumab and nivolumab Details
Renal cell carcinoma, Lung cancer, Multiple myeloma, Cancer

Phase 1/2

Data readout

Mupadolimab + pembrolizumab Details
HPV+ oropharyngeal cancer, Head and neck cancer, Non-small cell lung carcinoma, Cancer

Phase 1b

Update

Soquelitinib (CPI-818) (ITK inhibitor) Details
Cutaneous T cell lymphoma, Lymphoma, Cancer, Blood cancer

Phase 1

Data readout

Failed

Discontinued